News Unlocking a New Milestone: US FDA Grants QIDP Status to VRP-034! We are proud to share a landmark achievement in our journey at Venus Remedies Limited—one that shines a global spotlight on India’s role in tackling one of the world’s most pressing healthcare challenges: antimicrobial resistance (AMR) The U.S. Food and Drug Administration (FDA) has awarded Qualified
partnership Venus Remedies x Infex to Combat Antimicrobial Resistance in India Congratulations, Venusians. We have yet again marked another day on the calendar with gold! Venus Remedies Ltd. is delighted to announce a significant partnership with UK-based anti-infective drug development company, Infex Therapeutics. The alliance aims to tackle drug-resistant Gram-negative bacterial infections via MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor. Under this
News Featured Venus Remedies partners with UK-based Infex Therapeutics to develop anti-bacterial MET-X in India Bringing a First-in-Class MBL Inhibitor to India: Venus Remedies Licenses MET-X Venus Remedies has taken a significant step in combating Antimicrobial Resistance (AMR) by securing exclusive licensing rights for MET-X, an innovative anti-bacterial drug from UK-based Infex Therapeutics. This landmark partnership will enable Venus Remedies to develop, gain regulatory approvals,
